Kanvas Biosciences

Princeton-based spatial biology company building a microbiome drug discovery, screening, and manufacturing platform. Lead candidate KAN-001 is a live biotherapeutic for solid-tumor patients who do not respond to immune checkpoint inhibitors. Spinout from Cornell, founded 2020.